SK9122003A3 - Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors - Google Patents

Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors Download PDF

Info

Publication number: SK9122003A3
Authority: SK; Slovakia
Prior art keywords: dihydro; isoquinolin; group; formula; compound
Prior art date: 2000-12-23

Application number

SK912-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Guy Georges

Adelbert Grossmann

Olaf Mundigl

Der Saal Wolfgang Von

Tim Sattelkau

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-23

Filing date

2001-12-21

Publication date

2004-02-03

2001-12-21 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-02-03 Publication of SK9122003A3 publication Critical patent/SK9122003A3/sk

Links

230000004663 cell proliferation Effects 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title claims description 7
239000003112 inhibitor Substances 0.000 title claims description 5
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title description 16
150000001875 compounds Chemical class 0.000 claims abstract description 51
238000000034 method Methods 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
230000008569 process Effects 0.000 claims abstract description 4
-1 amino- Chemical class 0.000 claims description 41
125000000217 alkyl group Chemical group 0.000 claims description 19
125000001424 substituent group Chemical group 0.000 claims description 17
150000003839 salts Chemical class 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 12
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
102000003964 Histone deacetylase Human genes 0.000 claims description 8
108090000353 Histone deacetylase Proteins 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
125000006239 protecting group Chemical group 0.000 claims description 8
125000003282 alkyl amino group Chemical group 0.000 claims description 7
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
239000000460 chlorine Substances 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000005236 alkanoylamino group Chemical group 0.000 claims description 5
125000005530 alkylenedioxy group Chemical group 0.000 claims description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
125000001041 indolyl group Chemical group 0.000 claims description 4
RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
125000004434 sulfur atom Chemical group 0.000 claims description 4
NIDFZDATJZQXTB-UHFFFAOYSA-N 8-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyoctanamide Chemical compound C1=CC=C2CN(CCCCCCCC(=O)NO)CCC2=C1 NIDFZDATJZQXTB-UHFFFAOYSA-N 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
125000002009 alkene group Chemical group 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
239000011737 fluorine Substances 0.000 claims description 3
238000007327 hydrogenolysis reaction Methods 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
WSOCEYYLZHIVEI-UHFFFAOYSA-N 8-(6,7-diethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyoctanamide Chemical compound C1CN(CCCCCCCC(=O)NO)CC2=C1C=C(OCC)C(OCC)=C2 WSOCEYYLZHIVEI-UHFFFAOYSA-N 0.000 claims description 2
CNUTXVMVZXKCPJ-UHFFFAOYSA-N 8-(6,7-dimethoxy-1-phenyl-3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyoctanamide Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(CCCCCCCC(=O)NO)C1C1=CC=CC=C1 CNUTXVMVZXKCPJ-UHFFFAOYSA-N 0.000 claims description 2
GWBJXKKKWGIYMG-UHFFFAOYSA-N 8-(6,7-dimethoxy-1-propan-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyoctanamide Chemical compound C1CN(CCCCCCCC(=O)NO)C(C(C)C)C2=C1C=C(OC)C(OC)=C2 GWBJXKKKWGIYMG-UHFFFAOYSA-N 0.000 claims description 2
MIIOZNKTWSSHFH-UHFFFAOYSA-N 8-(6,7-dimethoxy-3-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyoctanamide Chemical compound C1C(C)N(CCCCCCCC(=O)NO)CC2=C1C=C(OC)C(OC)=C2 MIIOZNKTWSSHFH-UHFFFAOYSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
241000790917 Dioxys <bee> Species 0.000 claims 2
RZIWVBYJMFCTQG-UHFFFAOYSA-N 8-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyoctanamide Chemical compound C1CN(CCCCCCCC(=O)NO)CC2=C1C=C(OC)C(OC)=C2 RZIWVBYJMFCTQG-UHFFFAOYSA-N 0.000 claims 1
125000002947 alkylene group Chemical group 0.000 claims 1
125000005237 alkyleneamino group Chemical group 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 5
239000003276 histone deacetylase inhibitor Substances 0.000 abstract description 5
238000004519 manufacturing process Methods 0.000 abstract description 3
229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
AKVLPQQYGLOPQN-UHFFFAOYSA-N 8-bromo-n-phenylmethoxyoctanamide Chemical compound BrCCCCCCCC(=O)NOCC1=CC=CC=C1 AKVLPQQYGLOPQN-UHFFFAOYSA-N 0.000 description 27
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
239000002253 acid Substances 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 19
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 15
239000002904 solvent Substances 0.000 description 13
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
239000012442 inert solvent Substances 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000002585 base Substances 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
229910000027 potassium carbonate Inorganic materials 0.000 description 8
238000004440 column chromatography Methods 0.000 description 7
239000003701 inert diluent Substances 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000000243 solution Substances 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
238000000746 purification Methods 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
230000021736 acetylation Effects 0.000 description 4
238000006640 acetylation reaction Methods 0.000 description 4
150000008064 anhydrides Chemical class 0.000 description 4
230000001028 anti-proliverative effect Effects 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
230000009467 reduction Effects 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000006947 Histones Human genes 0.000 description 3
108010033040 Histones Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 2
ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 description 2
MSWGCPVLNRTAHF-UHFFFAOYSA-N 8-(3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylmethoxyoctanamide Chemical compound C1CC2=CC=CC=C2CN1CCCCCCCC(=O)NOCC1=CC=CC=C1 MSWGCPVLNRTAHF-UHFFFAOYSA-N 0.000 description 2
WKDSBNSWFFWQQD-UHFFFAOYSA-N 8-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylmethoxyoctanamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCCCCC(=O)NOCC1=CC=CC=C1 WKDSBNSWFFWQQD-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000003893 Histone acetyltransferases Human genes 0.000 description 2
108090000246 Histone acetyltransferases Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
108010047956 Nucleosomes Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
150000001266 acyl halides Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000920 calcium hydroxide Substances 0.000 description 2
229910001861 calcium hydroxide Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000003480 eluent Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000012458 free base Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
WRRGQOIIFBCTEX-UHFFFAOYSA-N n-phenylmethoxyoctanamide Chemical compound CCCCCCCC(=O)NOCC1=CC=CC=C1 WRRGQOIIFBCTEX-UHFFFAOYSA-N 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
229910000510 noble metal Inorganic materials 0.000 description 2
210000001623 nucleosome Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910001950 potassium oxide Inorganic materials 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
VCQURUZYYSOUHP-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 2,2,2-trifluoroacetate Chemical compound FC1=C(F)C(F)=C(OC(=O)C(F)(F)F)C(F)=C1F VCQURUZYYSOUHP-UHFFFAOYSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
RPROHCOBMVQVIV-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole Chemical group N1C2=CC=CC=C2C2=C1CCNC2 RPROHCOBMVQVIV-UHFFFAOYSA-N 0.000 description 1
CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
SNZGNULMZUIKAA-UHFFFAOYSA-N 3-[3-(3,4-dihydro-1h-isoquinolin-2-yl)propoxy]-n-hydroxypropanamide Chemical compound C1=CC=C2CN(CCCOCCC(=O)NO)CCC2=C1 SNZGNULMZUIKAA-UHFFFAOYSA-N 0.000 description 1
KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical class C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
NVKGJHAQGWCWDI-UHFFFAOYSA-N 4-[4-amino-2-(trifluoromethyl)phenyl]-3-(trifluoromethyl)aniline Chemical compound FC(F)(F)C1=CC(N)=CC=C1C1=CC=C(N)C=C1C(F)(F)F NVKGJHAQGWCWDI-UHFFFAOYSA-N 0.000 description 1
SHOWAGCIRTUYNA-UHFFFAOYSA-N 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydron;chloride Chemical compound [Cl-].C1C[NH2+]CC2=C1C=C(OC)C(OC)=C2 SHOWAGCIRTUYNA-UHFFFAOYSA-N 0.000 description 1
XCBCMNDFDVDUDF-UHFFFAOYSA-N 6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound [Cl-].C1=2C=C(OC)C(OC)=CC=2CC[NH2+]C1C1=CC=CC=C1 XCBCMNDFDVDUDF-UHFFFAOYSA-N 0.000 description 1
IGOOJGVJTBWOAB-UHFFFAOYSA-N 6,7-dimethoxy-1-propan-2-yl-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1CNC(C(C)C)C2=C1C=C(OC)C(OC)=C2 IGOOJGVJTBWOAB-UHFFFAOYSA-N 0.000 description 1
AFFAKYIZHAGJMU-UHFFFAOYSA-N 6,7-dimethoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound [Cl-].C1[NH2+]C(C)CC2=C1C=C(OC)C(OC)=C2 AFFAKYIZHAGJMU-UHFFFAOYSA-N 0.000 description 1
FKGVLRTUFRADOH-UHFFFAOYSA-N 6-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyhexanamide Chemical compound C1=CC=C2CN(CCCCCC(=O)NO)CCC2=C1 FKGVLRTUFRADOH-UHFFFAOYSA-N 0.000 description 1
ZGDGVKFONHSFIW-UHFFFAOYSA-N 7-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxy-3-methylheptanamide Chemical compound C1=CC=C2CN(CCCCC(C)CC(=O)NO)CCC2=C1 ZGDGVKFONHSFIW-UHFFFAOYSA-N 0.000 description 1
HSHPGTWGSDHVBP-UHFFFAOYSA-N 7-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxy-4-methylheptanamide Chemical compound C1=CC=C2CN(CCCC(C)CCC(=O)NO)CCC2=C1 HSHPGTWGSDHVBP-UHFFFAOYSA-N 0.000 description 1
QCSBWPUFINTZOW-UHFFFAOYSA-N 7-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxy-5-methylheptanamide Chemical compound C1=CC=C2CN(CCC(CCCC(=O)NO)C)CCC2=C1 QCSBWPUFINTZOW-UHFFFAOYSA-N 0.000 description 1
LOEFBHPFPGYXOH-UHFFFAOYSA-N 7-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxyheptanamide Chemical compound C1=CC=C2CN(CCCCCCC(=O)NO)CCC2=C1 LOEFBHPFPGYXOH-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
NHIZNOJOXBYTLC-UHFFFAOYSA-N 8-(3,4-dihydro-1h-isoquinolin-2-yl)-n-hydroxy-2-methyloctanamide Chemical compound C1=CC=C2CN(CCCCCCC(C)C(=O)NO)CCC2=C1 NHIZNOJOXBYTLC-UHFFFAOYSA-N 0.000 description 1
DDYNKVBEBPTHFP-UHFFFAOYSA-N 8-(6,7-dimethoxy-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)octanoic acid Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(CCCCCCCC(O)=O)C1C1=CC=CC=C1 DDYNKVBEBPTHFP-UHFFFAOYSA-N 0.000 description 1
GHMITHIEGHUDAN-UHFFFAOYSA-N 8-(6,7-dimethoxy-1-phenyl-3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylmethoxyoctanamide Chemical compound C=1C=CC=CC=1C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCCCCC(=O)NOCC1=CC=CC=C1 GHMITHIEGHUDAN-UHFFFAOYSA-N 0.000 description 1
YCUFPDUVMYLNSK-UHFFFAOYSA-N 8-(6,7-dimethoxy-1-propan-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylmethoxyoctanamide Chemical compound CC(C)C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCCCCC(=O)NOCC1=CC=CC=C1 YCUFPDUVMYLNSK-UHFFFAOYSA-N 0.000 description 1
ANCTYVQSMJOSGQ-UHFFFAOYSA-N 8-(6,7-dimethoxy-3-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylmethoxyoctanamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CC(C)N1CCCCCCCC(=O)NOCC1=CC=CC=C1 ANCTYVQSMJOSGQ-UHFFFAOYSA-N 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
VULBPAKAYYMJNJ-UHFFFAOYSA-N C1N(CCC2=CC=CC=C12)CCCC(C(CC(=O)NO)C)=O Chemical compound C1N(CCC2=CC=CC=C12)CCCC(C(CC(=O)NO)C)=O VULBPAKAYYMJNJ-UHFFFAOYSA-N 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
UKNVEVLRANZQTK-UHFFFAOYSA-N O-benzylhydroxylamine 8-(6,7-dimethoxy-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl)octanoic acid Chemical compound NOCC1=CC=CC=C1.C1C(C)N(CCCCCCCC(O)=O)CC2=C1C=C(OC)C(OC)=C2 UKNVEVLRANZQTK-UHFFFAOYSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
150000001264 acyl cyanides Chemical class 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
150000008209 arabinosides Chemical class 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
HLZAXMDOWBOHLS-UHFFFAOYSA-N n-(4-cyanophenyl)-4,4,4-trifluoro-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylbutanamide Chemical compound C=1C=C(C#N)C=CC=1NC(=O)C(O)(C)C(C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 HLZAXMDOWBOHLS-UHFFFAOYSA-N 0.000 description 1
QCBXGTJYUUEIEF-UHFFFAOYSA-N n-hydroxy-8-(6-phenyl-3,4-dihydro-1h-isoquinolin-2-yl)octanamide Chemical compound C=1C=C2CN(CCCCCCCC(=O)NO)CCC2=CC=1C1=CC=CC=C1 QCBXGTJYUUEIEF-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000006308 propyl amino group Chemical group 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Other In-Based Heterocyclic Compounds (AREA)

SK912-2003A 2000-12-23 2001-12-21 Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors SK9122003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00128487		2000-12-23
PCT/EP2001/015390 WO2002051842A1 (fr)	2000-12-23	2001-12-21	Derives de tetrahydropyridine, leur preparation et leur utilisation en tant qu'inhibiteurs de proliferation cellulaire

Publications (1)

Publication Number	Publication Date
SK9122003A3 true SK9122003A3 (en)	2004-02-03

Family

ID=8170814

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK912-2003A SK9122003A3 (en)	2000-12-23	2001-12-21	Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors

Country Status (27)

Country	Link
US (1)	US6800638B2 (fr)
EP (1)	EP1353921B1 (fr)
JP (1)	JP2004516325A (fr)
KR (1)	KR100836545B1 (fr)
CN (1)	CN1213046C (fr)
AR (1)	AR035513A1 (fr)
AT (1)	ATE323700T1 (fr)
AU (1)	AU2002226397B2 (fr)
BG (1)	BG107935A (fr)
BR (1)	BR0116402A (fr)
CA (1)	CA2431471A1 (fr)
CZ (1)	CZ20031940A3 (fr)
DE (1)	DE60118975T2 (fr)
EC (1)	ECSP034664A (fr)
ES (1)	ES2261519T3 (fr)
HU (1)	HUP0400554A2 (fr)
IL (1)	IL156131A0 (fr)
MA (1)	MA26976A1 (fr)
MX (1)	MXPA03005713A (fr)
NO (1)	NO20032830L (fr)
NZ (1)	NZ526189A (fr)
PL (1)	PL365531A1 (fr)
RU (1)	RU2276140C2 (fr)
SK (1)	SK9122003A3 (fr)
WO (1)	WO2002051842A1 (fr)
YU (1)	YU48803A (fr)
ZA (1)	ZA200304264B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6706686B2 (en)	2001-09-27	2004-03-16	The Regents Of The University Of Colorado	Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (fr)	2001-10-16	2011-07-27	Sloan-Kettering Institute For Cancer Research	Traitement des maladies neurodegeneratives et du cancer du cerveau
WO2003083323A1 (fr)	2002-04-01	2003-10-09	Ranko Rakanovic	Élément élastique en caoutchouc
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7250514B1 (en)	2002-10-21	2007-07-31	Takeda San Diego, Inc.	Histone deacetylase inhibitors
AU2003900608A0 (en) *	2003-02-11	2003-02-27	Fujisawa Pharmaceutical Co., Ltd.	Hdac inhibitor
US7375228B2 (en)	2003-03-17	2008-05-20	Takeda San Diego, Inc.	Histone deacetylase inhibitors
EP1633751A1 (fr) *	2003-06-16	2006-03-15	Chroma Therapeutics Limited	Derives de carboline et de betacarboline inhibiteurs de l'enzyme hdac
CN1905881A (zh) *	2003-11-26	2007-01-31	阿托恩药品公司	二胺和亚氨二醋酸异羟肟酸衍生物
US20050137234A1 (en) *	2003-12-19	2005-06-23	Syrrx, Inc.	Histone deacetylase inhibitors
WO2005065681A1 (fr) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	Derives de n-hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide et composes associes en tant qu'inhibiteurs d'histone deacetylase pour le traitement du cancer
US7642275B2 (en)	2004-12-16	2010-01-05	Takeda San Diego, Inc.	Histone deacetylase inhibitors
JP2008530136A (ja)	2005-02-14	2008-08-07	ミイカナセラピューティクスインコーポレイテッド	ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
GB0509223D0 (en) *	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Enzyme inhibitors
JP2008540574A (ja) *	2005-05-11	2008-11-20	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
CA2615105A1 (fr) *	2005-07-14	2007-01-25	Takeda San Diego, Inc.	Inhibiteurs de l'histone deacetylase
EP2275096A3 (fr)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese par modulation des recepteurs muscariniques
EP2258357A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse avec inhibiteur de l'acetylcholinestérase
WO2007047978A2 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr)	2005-10-31	2011-04-27	Braincells, Inc.	Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
EP1976835A2 (fr) *	2006-01-13	2008-10-08	Takeda San Diego, Inc.	Inhibiteurs des histone desacetylases
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenèse par modulation de l'angiotensine
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (fr)	2006-09-08	2008-03-13	Braincells, Inc.	Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
TWI425945B (zh) *	2007-05-28	2014-02-11	Seldar Pharma Inc	四氫異喹啉－１－酮衍生物或其鹽
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
JP5838157B2 (ja) *	2009-07-22	2015-12-24	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅＢｏａｒｄＯｆＴｒｕｓｔｅｅｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＩｌｌｉｎｏｉｓ	Ｈｄａｃ阻害剤およびそれを用いる治療法
CN102153549B (zh) *	2010-12-14	2012-11-14	华东理工大学	γ咔啉化合物、制备方法和用途
CA2908542C (fr)	2013-04-29	2017-08-01	Chong Kun Dang Pharmaceutical Corp.	Nouveaux composes pour inhibiteurs selectifs d'histone desacetylases et composition pharmaceutique les comprenant
WO2015051035A1 (fr)	2013-10-01	2015-04-09	The J. David Gladstone Institutes	Compositions, systèmes et procédés pour le criblage de médicament de bruit d'expression génétique et leurs utilisations
CN108084178B (zh) *	2018-01-04	2020-09-01	济南大学	一类含有四氢-β-咔碄结构的异羟肟酸类化合物的用途
CN108558653A (zh) *	2018-05-14	2018-09-21	湖南华腾制药有限公司	赛乐西帕中间体及赛乐西帕的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU196758B (en) *	1986-05-21	1989-01-30	Gyogyszerkutato Intezet	Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
WO1990002119A1 (fr) *	1988-08-18	1990-03-08	Banyu Pharmaceutical Co., Ltd.	Derives de 1,2,3,4-tetrahydro-isoquinoline
US5369108A (en) *	1991-10-04	1994-11-29	Sloan-Kettering Institute For Cancer Research	Potent inducers of terminal differentiation and methods of use thereof
WO1998007421A1 (fr) *	1996-08-16	1998-02-26	Ishihara Sangyo Kaisha, Ltd.	Composition medicinale
WO1998015525A1 (fr) *	1996-10-07	1998-04-16	Sumitomo Pharmaceuticals Co., Ltd.	Acides hydroxamiques
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
JP2003525203A (ja) *	1999-03-22	2003-08-26	ダーウィン・ディスカバリー・リミテッド	ヒドロキサムおよびカルボン酸誘導体

2001
- 2001-12-06 AR ARP010105675A patent/AR035513A1/es not_active Application Discontinuation
- 2001-12-21 AT AT01995721T patent/ATE323700T1/de not_active IP Right Cessation
- 2001-12-21 SK SK912-2003A patent/SK9122003A3/sk unknown
- 2001-12-21 IL IL15613101A patent/IL156131A0/xx unknown
- 2001-12-21 BR BR0116402-3A patent/BR0116402A/pt not_active IP Right Cessation
- 2001-12-21 CA CA002431471A patent/CA2431471A1/fr not_active Abandoned
- 2001-12-21 US US10/451,757 patent/US6800638B2/en not_active Expired - Fee Related
- 2001-12-21 EP EP01995721A patent/EP1353921B1/fr not_active Expired - Lifetime
- 2001-12-21 YU YU48803A patent/YU48803A/sh unknown
- 2001-12-21 ES ES01995721T patent/ES2261519T3/es not_active Expired - Lifetime
- 2001-12-21 RU RU2003122190/04A patent/RU2276140C2/ru active
- 2001-12-21 KR KR1020037008028A patent/KR100836545B1/ko not_active Expired - Fee Related
- 2001-12-21 WO PCT/EP2001/015390 patent/WO2002051842A1/fr not_active Ceased
- 2001-12-21 DE DE60118975T patent/DE60118975T2/de not_active Expired - Fee Related
- 2001-12-21 CZ CZ20031940A patent/CZ20031940A3/cs unknown
- 2001-12-21 NZ NZ526189A patent/NZ526189A/en unknown
- 2001-12-21 MX MXPA03005713A patent/MXPA03005713A/es active IP Right Grant
- 2001-12-21 AU AU2002226397A patent/AU2002226397B2/en not_active Ceased
- 2001-12-21 PL PL01365531A patent/PL365531A1/xx not_active Application Discontinuation
- 2001-12-21 JP JP2002552937A patent/JP2004516325A/ja not_active Ceased
- 2001-12-21 HU HU0400554A patent/HUP0400554A2/hu unknown
- 2001-12-21 CN CNB018212050A patent/CN1213046C/zh not_active Expired - Fee Related
2003
- 2003-05-30 ZA ZA200304264A patent/ZA200304264B/en unknown
- 2003-06-20 NO NO20032830A patent/NO20032830L/no not_active Application Discontinuation
- 2003-06-20 MA MA27207A patent/MA26976A1/fr unknown
- 2003-06-22 EC EC2003004664A patent/ECSP034664A/es unknown
- 2003-06-23 BG BG107935A patent/BG107935A/bg unknown

Also Published As

Publication number	Publication date
YU48803A (sh)	2006-05-25
KR100836545B1 (ko)	2008-06-10
PL365531A1 (en)	2005-01-10
EP1353921A1 (fr)	2003-10-22
EP1353921B1 (fr)	2006-04-19
MXPA03005713A (es)	2003-10-06
US6800638B2 (en)	2004-10-05
HUP0400554A2 (hu)	2004-06-28
CZ20031940A3 (cs)	2003-10-15
CN1483033A (zh)	2004-03-17
JP2004516325A (ja)	2004-06-03
BG107935A (bg)	2004-08-31
US20040053960A1 (en)	2004-03-18
AR035513A1 (es)	2004-06-02
NO20032830D0 (no)	2003-06-20
CN1213046C (zh)	2005-08-03
ZA200304264B (en)	2004-08-30
DE60118975D1 (de)	2006-05-24
RU2003122190A (ru)	2005-02-27
CA2431471A1 (fr)	2002-07-04
RU2276140C2 (ru)	2006-05-10
AU2002226397B2 (en)	2006-10-05
WO2002051842A1 (fr)	2002-07-04
NZ526189A (en)	2004-10-29
MA26976A1 (fr)	2004-12-20
IL156131A0 (en)	2003-12-23
BR0116402A (pt)	2003-11-11
ECSP034664A (es)	2003-07-25
NO20032830L (no)	2003-08-04
KR20030063424A (ko)	2003-07-28
ATE323700T1 (de)	2006-05-15
DE60118975T2 (de)	2006-12-21
ES2261519T3 (es)	2006-11-16

Publication	Publication Date	Title
EP1353921B1 (fr)	2006-04-19	Derives de tetrahydropyridine, leur preparation et leur utilisation en tant qu'inhibiteurs de proliferation cellulaire
AU2002246053B2 (en)	2005-02-17	Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
AU2002226397A1 (en)	2003-01-23	Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
AU2002246053A1 (en)	2003-02-13	Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
AU2002254991B2 (en)	2007-07-19	Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
CN112300153B (zh)	2023-06-13	一种杂环化合物、药物组合物和用途
AU2002254991A1 (en)	2003-04-17	Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
CN117069696B (zh)	2024-04-26	一种双靶点小分子抑制剂及其制备方法和应用
WO2005080392A1 (fr)	2005-09-01	Dérive de pyrazoloquinolone et utilisation de celui-ci
CN103373986B (zh)	2016-10-05	克里唑替尼前药及其制备方法与用途
CN115368306B (zh)	2023-12-22	含四氢异喹啉类结构的hdac抑制剂、组合物及其用途
AU687414B2 (en)	1998-02-26	Piperidinyl substituted methanoanthracenes as D1/D2-antagonists and 5HT2-serotanin-antagonists